Calamos Advisors LLC Revance Therapeutics, Inc. Transaction History

Calamos Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	BUY	$24.7 - $37.61 $415,231 - $632,261	16,811 Added 207.24%	24,923 $630,000
Q1 2023 May 03, 2023	SELL	$18.36 - $35.27 $104,358 - $200,474	-5,684 Reduced 41.2%	8,112 $261,000
Q4 2022 Jan 25, 2023	SELL	$18.32 - $30.66 $1.17 Million - $1.96 Million	-63,874 Reduced 82.24%	13,796 $0
Q3 2022 Oct 24, 2022	BUY	$14.33 - $28.47 $1.11 Million - $2.21 Million	77,670 New	77,670 $2.1 Million
Q4 2020 Jan 27, 2021	SELL	$23.41 - $28.34 $1.47 Million - $1.77 Million	-62,599 Closed	0 $0
Q3 2020 Oct 26, 2020	BUY	$23.23 - $34.3 $684,657 - $1.01 Million	29,473 Added 88.97%	62,599 $1.58 Million
Q2 2020 Jul 27, 2020	BUY	$12.6 - $26.55 $417,387 - $879,495	33,126 New	33,126 $809,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Calamos Advisors LLC with notifications on news.